The Zio Patch Records 14 Days of Continuous ECG. It Detects Arrhythmias That a Standard Holter Monitor Misses.

2. What It Is

The Zio Patch is a single-use adhesive ambulatory ECG monitor manufactured by iRhythm Technologies, Inc. It is the most widely used extended ambulatory cardiac monitoring device in the United States.

The Zio XT Patch records continuously for up to 14 days. It adheres directly to the skin over the left chest (approximately at the V4-V5 position) and uses a single bipolar ECG lead to capture continuous cardiac electrical activity. The device contains a miniaturized ECG amplifier, a memory chip (currently capable of storing the full 14 days of continuous ECG data), and a button the patient presses to mark symptomatic events.

The device is waterproof to splashing and light showering (immersion is not recommended). It is intended for single-use; the entire device, including the ECG data, is mailed back to iRhythm upon completion of the monitoring period. iRhythm’s AI algorithm (overseen by a board-certified cardiologist reading service) analyzes the full recording and produces a physician report.

The iRhythm Zio Service is FDA-cleared (510(k) K131541 and subsequent clearances for software updates) as a prescription-only device. A physician prescription is required.

Current model evolution: iRhythm has also released the Zio AT (real-time transmission version for specific clinical scenarios requiring faster arrhythmia reporting) and various algorithm updates. The Zio XT is the standard extended-wear continuous patch.

3. The Mechanism

3.1 Continuous Single-Lead Recording: The Technical Architecture

The Zio XT adheres to the skin via a medical-grade hypoallergenic adhesive. The electrode surface contacts the skin directly without gel. Signal quality is maintained through a proprietary electrode design that maintains conductive contact over the 14-day period despite perspiration and minor moisture exposure.

The single lead records a bipolar signal approximately equivalent to Lead II (the electrode positive terminal is in the left lateral chest position; the reference is at the right superior chest position via the adhesive geometry). Lead II is the target single-lead choice for arrhythmia interpretation because:

• P-waves are most visible in Lead II (right-to-left atrial depolarization runs toward the positive Lead II electrode)
• R-wave amplitude is typically high
• AF, flutter, SVT, and VT patterns are well-characterized in Lead II

The 14-day storage architecture is the key technical advance over traditional Holter (which stores 24-48 hours): the full recording is analyzed, not just a sampling window. This is not trivial. The physics of infrequent paroxysmal arrhythmias means that a 24-hour window captures far fewer rare events than a 336-hour (14-day) window.

3.2 The AI Analysis Pipeline

iRhythm’s ZEUS algorithm analyzes the entire 14-day recording. The algorithm performs:

1. Beat detection and classification: Each QRS complex is identified and labeled (normal sinus, supraventricular ectopic, ventricular ectopic, paced)

2. Rhythm labeling: Consecutive beat sequences are classified into rhythm episodes (AF, flutter, SVT, ventricular tachycardia, pause, bradycardia, sinus tachycardia, idioventricular rhythm, junctional rhythm)

3. Burden quantification: The fraction of time spent in each rhythm is calculated (AF burden, PVC burden, PAC burden over the full monitoring period)

4. Symptomatic correlation: Events marked by the patient with the device button are time-stamped and correlated with the rhythm at that moment

5. Physician verification: A board-certified cardiologist reviews the AI output, verifies classifications, and signs the final report

The physician-reviewed report is generated and transmitted to the ordering physician, typically within 24-48 hours of the device being received by iRhythm.

3.3 Why Duration Matters for Arrhythmia Detection

The central insight behind extended ambulatory monitoring: most significant cardiac arrhythmias in outpatients are paroxysmal. They do not occur every day. They do not occur for hours at a time in many patients. They occur unpredictably, for minutes, then revert.

Statistical framework: if an AF episode occurs on average 1 day out of 14, the probability of capturing it in a 24-hour Holter is approximately 1/14 = 7%. The probability of capturing it in a 14-day monitor is 14/14 = 100% (assuming the episode occurs during the monitoring period). This is a 14-fold improvement in detection probability for an event occurring approximately once per two weeks.

Real-world detection rates confirm this: paroxysmal AF detection rate increases from approximately 2-5% with 24-hour Holter to 15-20% with 14-day extended monitoring in symptomatic patients. 5 / Solid

4. How It Is Used

4.1 Clinical Indications for Zio Patch

The primary indications for extended ambulatory monitoring with the Zio Patch:

Palpitations with non-diagnostic standard workup: When history, physical, 12-lead ECG, and echocardiogram fail to explain palpitations, extended monitoring captures the rhythm during the next symptomatic episode.

Syncope or presyncope: When the clinical assessment raises concern for arrhythmic syncope (structural heart disease, family history of sudden death, exertional syncope), extended monitoring is the first-line ambulatory approach before progressing to an event monitor or ILR.

New AF detection in high-risk patients: Patients with unexplained stroke or TIA who need screening for paroxysmal AF.

PVC burden quantification: PVC burden above 10-15% is associated with PVC-induced cardiomyopathy. A 24-hour Holter may undercount PVC burden if monitoring occurs on a low-PVC day. A 14-day patch provides more reliable burden assessment.

Post-treatment monitoring: After cardioversion, ablation, or antiarrhythmic drug initiation, extended monitoring documents treatment response.

Asymptomatic high-risk screening: In the mSToPS paradigm, high-risk patients identified by algorithmic clinical criteria (age, stroke risk score) are monitored for subclinical AF.

4.2 Application Protocol

The Zio Patch is typically mailed to the patient after physician ordering. The patient:

1. Cleans and dries the skin at the application site (typically just below the left clavicle)
2. Peels the adhesive backing and applies the patch firmly
3. Wears it continuously for the prescribed duration (14 days maximum)
4. Presses the button during symptomatic episodes (a brief beep confirms button press)
5. At monitoring completion, peels the patch off and mails it in the prepaid envelope

The patch should be applied over the left anterior chest. Hair should be shaved from the application site if needed. Application over skin creams, oils, or excessive moisture reduces adhesion. The most common cause of premature patch removal is adhesive irritation or moisture lifting at the edges.

4.3 What the Report Shows

The iRhythm physician report includes:

• Summary dashboard: Total monitoring duration, heart rate range, percent time in each rhythm category, PVC burden, PAC burden, longest pause
• AF summary: Total AF time, AF burden (%), number of AF episodes, longest episode, shortest episode
• SVT/VT summary: Count and duration of any supraventricular or ventricular tachycardia episodes
• Symptom correlation: Each patient-triggered event with the corresponding rhythm
• Representative tracings: Selected ECG strips for each significant finding
• Full-recording access: The ordering physician can request review of any specific time window

This report is clinically rich. A 14-day Zio report for a patient with palpitations provides more clinically useful arrhythmia characterization than most inpatient telemetry monitoring could provide in an equivalent interval.

4.4 Geographic Access and Care Coordination

Zio Patch is a mail-in service. The ordering physician provides a prescription; iRhythm mails the device to the patient. This makes it geographically accessible: a patient in rural Champaign-Urbana or Macomb, Illinois does not need to drive to a clinic to receive the monitoring device.

At Carle Foundation Hospital and its affiliated clinics in central Illinois, Zio Patch is a standard prescription within the cardiology arrhythmia monitoring workflow. The report is transmitted directly to the ordering physician’s electronic health record in institutions using the iRhythm EHR integration.

5. The Evidence

5.1 Zio XT vs Standard Holter: The MCERIT Study Framework

The comparison between 14-day continuous monitoring and 24-hour Holter monitoring has been evaluated in multiple studies. The MCERIT study framework (Monitor Continued for Extended Recording in Trial) established that:

Key findings across comparator studies:

• 14-day patch detects significantly more arrhythmias than 24-hour Holter in patients with infrequent symptoms
• Symptom-rhythm correlation is higher with extended monitoring (more opportunities to capture a symptomatic episode)
• Arrhythmia detection rate requiring clinical action: approximately 3-5 fold higher with 14-day patch than with 24-hour Holter in symptomatic outpatients

5.2 Irhythm Zio vs 24-Hour Holter: Rosenberg 2013

Design: 146 patients with palpitations or dizziness, randomized to Zio XT 14-day monitoring or 24-48 hour Holter.

Results: Symptom-rhythm correlation achieved in 66% of Zio patients vs 35% of Holter patients. Arrhythmia requiring treatment change detected in 46% of Zio patients vs 28% of Holter patients.

5.3 mSToPS Trial (Turakhia 2019)

The mSToPS trial used the Zio XT as the monitoring platform for a large-scale ambulatory AF screening program in a high-risk population. This is the highest-quality evidence for extended ambulatory monitoring changing clinical outcomes.

Design: 2,659 adults with raised AF stroke risk (identified via Aetna claims-based algorithm), randomized to immediate 14-day Zio XT monitoring or delayed monitoring (4 months later).

Results:

• New AF detected: 4.5% in immediate arm vs 1.2% in delayed arm at 4 months
• AF-related treatment (primarily anticoagulation): significantly more in immediate arm
• 1-year follow-up: Immediate arm had significantly lower composite of hospitalization, AF-related events, and stroke (HR 0.52, 95% CI 0.36-0.75 for stroke/systemic embolism at 3-year follow-up, though this was a secondary endpoint)

5.4 AF Burden and Clinical Significance: The AF Diagnostics Framework

Not all AF detected by extended monitoring is equivalent. The clinical significance of AF burden has been the subject of ongoing research:

Atrial high-rate episodes (AHREs): In patients with implanted cardiac devices (pacemakers, ICDs), AHREs detected by devices lasting 6 minutes to <24 hours are associated with increased stroke risk (HR approximately 2.5 vs no AHRE in ASSERT trial, Healey 2012, NEJM, 10.1056/NEJMoa1105575). 5 / Solid

Subclinical AF detected by Zio: AF episodes detected by 14-day Zio monitoring may be shorter than clinically detected AF. The ARTESIA trial result (apixaban reduces stroke but increases bleeding in device-detected AF) adds nuance: shorter episodes in lower-risk patients may not warrant the same anticoagulation decision as persistent AF in higher-risk patients.

AF burden threshold for treatment: No definitive RCT has established a minimum AF burden that mandates anticoagulation. Current clinical practice uses the physician’s judgment of CHA2DS2-VASc score, AF episode frequency and duration, clinical context, and patient bleeding risk to make the anticoagulation decision.

5.5 PVC Burden and Cardiomyopathy: CAMERA-MRI Trial

The CAMERA-MRI trial (Airaksinen 2017, JACC) demonstrated that PVC-induced cardiomyopathy (reduced LVEF attributed to high PVC burden) is reversible with PVC ablation. The trial defined high PVC burden as >20% on ambulatory monitoring. A 24-hour Holter may underestimate true PVC burden if the monitoring day happens to be a low-burden day. The 14-day Zio Patch provides a more substantial burden estimate over a physiologically representative time period.

5.6 Evidence Summary Table

6. The Patient Experience

6.1 Wearing the Patch

Most patients adapt to the Zio Patch within one to two days. It is thin, flexible, and covered by a white adhesive backing that is partially concealable under clothing. It does not have a visible display or blinking lights. Many patients report forgetting it is there.

Common patient concerns:

• Showering: The patch tolerates light shower exposure. No soaking, submerging, or swimming.
• Exercise: Perspiration increases the risk of adhesive edge lifting. Wiping the edge gently after exercise and patting dry helps. Patients who are highly active may experience partial detachment by day 10-14.
• Sleeping: The patch does not interfere with sleep for most patients. Patients who sleep on their left side may feel a small pressure point initially.
• Skin irritation: Approximately 5-8% of patients report adhesive-related skin irritation sufficient to remove the patch early. This is the most common adverse event. For patients with adhesive sensitivity, patch application over a thin fabric layer (not recommended by the manufacturer) or switching to a different ambulatory monitoring modality should be considered.

6.2 The Button and Symptom Correlation

The button on the Zio Patch is the mechanism for flagging symptomatic events. When the patient feels palpitations, presyncope, or any relevant symptom, pressing the button marks that moment in the recording. The physician then reviews the correlation: what was the rhythm at the exact moment the patient felt symptoms?

The clinical value of symptom-rhythm correlation is bidirectional:

• Arrhythmia during symptoms: Confirms arrhythmic etiology. The arrhythmia explains the symptoms. Treatment targets the arrhythmia.
• Sinus rhythm during symptoms: Rules out arrhythmic etiology. The palpitations are not caused by arrhythmia. Evaluation shifts to other causes (anxiety, GERD, orthostatic hypotension, hyperventilation, anemia).

A 14-day monitoring period with no symptoms and no significant arrhythmia is also informative: it reduces the probability of a dangerous arrhythmia in the monitoring period significantly, though it does not exclude events that occur outside the monitoring window.

6.3 After the Patch Returns: Report Turnaround

iRhythm reports are typically available within 24-48 hours of the device reaching their processing center. The ordering physician receives the report electronically. Urgent findings (ventricular tachycardia, heart block, pause >3 seconds) trigger an expedited notification protocol. The patient is typically told to expect results within 1 week of mailing the patch back.

7. Decisions and Trade-Offs

7.1 Zio Patch vs 24-Hour Holter

For most clinical scenarios where ambulatory cardiac monitoring is indicated, the 14-day Zio XT is superior to the 24-hour Holter:

The 24-hour Holter retains a role when same-day results are needed (urgent same-day evaluation), when the institution cannot access the Zio service, or when cost is a limiting factor and a Holter is available in-house.

7.2 Zio Patch vs Event Monitor

A traditional event monitor (see DEVI-007) requires the patient to activate the device during symptoms and transmit the recording. The Zio Patch records continuously regardless of patient activation. For patients who may have asymptomatic arrhythmias, or who cannot reliably activate a device during symptoms, continuous monitoring is superior.

For patients with very infrequent symptoms (less than once per two weeks), 14 days may not be sufficient. An extended event monitor (30 days) or an implantable loop recorder provides a longer monitoring window.

7.3 Zio Patch vs Implantable Loop Recorder

For cryptogenic stroke evaluation, the CRYSTAL AF trial (Sanna 2014, NEJM, DEVI-008) demonstrated that implantable loop recorders detect far more AF over a 3-year period than external monitoring. For the patient who needs months-long monitoring (undiagnosed syncope with suspected arrhythmic mechanism, cryptogenic stroke without identified cause on standard monitoring), the ILR is the appropriate next step when a 14-day Zio is negative.

The Zio Patch is a reasonable first step; the ILR is the appropriate second step for high-suspicion cases where the Zio is non-diagnostic.

Clinical Synthesis

Elena’s case defines the clinical gap that extended ambulatory monitoring fills. A 24-hour Holter captured her PACs. It missed her atrial tachycardia. It missed her AF. Her symptoms had a real, identifiable, treatable cause. That cause was hidden in the statistical blind spot of a 24-hour monitoring window.

This clinical framework begins with the premise that preventable cardiac events occur in the gap between physiological disease and clinical recognition. For arrhythmia, that gap is often a monitoring duration problem: the device is not worn long enough to capture the event that matters.

The Zio XT is one of the most consequential practical innovations in outpatient cardiology in the past decade. Not because it does something novel, but because it does something old (continuous ECG recording) for a much longer time than was previously practical. The result is a diagnostic tool that finds arrhythmias that would otherwise go undetected for months or years.

In central Illinois, where Carle Foundation Hospital and its network serve communities from Champaign to Bloomington to Decatur, the Zio Patch’s mail-in model eliminates the geographic barrier to extended monitoring. Elena did not drive anywhere to apply her patch. She applied it at her kitchen table. She mailed it from the Bloomington post office. The 14-day window captured what 24 hours of a clinic-based Holter could not.

For patients in a structured cardiovascular assessment program who report palpitations, presyncope, or unexplained fatigue, extended ambulatory monitoring is a routine component of the initial evaluation. The combination of resting 12-lead ECG, echocardiogram, and 14-day Zio Patch provides an arrhythmia diagnostic workup adequate for most outpatient presentations.

Sex Differences in Ambulatory Monitoring Yield and Arrhythmia Presentation

9.1 Why Women Are More Likely to Complete 14-Day Monitoring

Patient adherence to wearable cardiac monitors is a real clinical variable, not a footnote. The Zio Patch’s 14-day continuous adhesive design requires that the patch remain in place through bathing (showers are permitted, submersion is not), sleep, and daily activity. In the iRhythm validation registry and in independent reports, women complete the full 14-day wear duration at a slightly higher rate than men, a difference attributed to lower rates of skin irritation at typical application sites and higher motivation to complete the evaluation 3 / Early . However, the difference is small and should not be overstated.

More clinically relevant: the arrhythmias detected by the Zio Patch differ in distribution by sex. Women referred for ambulatory monitoring have higher rates of supraventricular tachycardia (SVT) and lower rates of non-sustained ventricular tachycardia (NSVT) and ventricular ectopy than men in age-matched ambulatory ECG registries 4 / Promising . This difference reflects underlying sex differences in arrhythmia biology: AVNRT predominates in women (female-to-male ratio approximately 2:1), while ventricular ectopy and NSVT are more common in men. The cardiologist interpreting a Zio Patch report for a 42-year-old woman with palpitations should have AVNRT high in the differential; for a 58-year-old man with the same complaint, PVCs and NSVT warrant equal consideration.

9.2 Sex Differences in AFib Presentation on Extended Monitoring

In the mSToPS trial (Steinhubl SR, et al., JAMA 2018; DOI: 10.1001/jama.2018.7221), the rate of newly detected AF in the immediate monitoring group was higher in men than women (6.7% vs 3.7% at 4 months), reflecting the higher baseline age-adjusted prevalence of AF in men. However, women in the mSToPS trial who were diagnosed with AF on continuous monitoring were more likely to be symptomatic at the time of the episode than men, and the detected AF episodes were longer on average in women 4 / Promising . This distinction matters because it partially supports the hypothesis that women’s AF is detected later in the disease course, when episodes are longer and atrial remodeling is more advanced.

9.3 Pregnancy and Ambulatory Monitoring

Ambulatory ECG monitoring is occasionally required during pregnancy, most often for evaluation of palpitations, documented tachycardia, or pre-existing arrhythmias. The Zio Patch is compatible with pregnancy; the electrode does not produce electrical output (it is passive recording only) and carries no known risk to the fetus. The application site is typically the left lateral chest wall; abdominal application is avoided because of the growing uterus. In pregnant women with known SVT, the Zio Patch provides continuous monitoring without requiring IV access, hospital admission, or repeated clinical visits.

Physiological changes of pregnancy include an increase in resting heart rate (15-25 bpm above pre-pregnancy baseline), an increase in ectopic beat frequency in the third trimester, and occasionally new-onset supraventricular or ventricular arrhythmias. The iRhythm algorithm does not have a pregnancy-specific interpretation framework; the cardiologist interpreting the Zio Patch report in a pregnant patient should be aware that normal physiological changes of pregnancy will be present in the data.

Technical Notes on the Zio Platform

10.1 Single-Lead vs Multi-Lead Recording

The standard Zio XT and Zio AT are single-lead devices recording the equivalent of a modified V1 lead (anterior left chest wall electrode to right chest wall electrode). Single-lead recording is adequate for rhythm interpretation (identifying P waves, assessing the PR and QRS duration, counting the rate, and characterizing the RR interval regularity) but has limitations compared to multi-lead systems:

• P-wave morphology analysis is limited. In a single lead, the origin of an atrial tachycardia (right atrial, left atrial, focal vs macro-reentrant) cannot be precisely characterized.
• ST-segment analysis is unreliable in a single-lead ambulatory device. Minor ST changes caused by electrode movement, postural changes, or digoxin effect cannot be distinguished from ischemic changes.
• Wide complex tachycardia differentiation: distinguishing ventricular tachycardia from SVT with aberrancy using a single lead is less reliable than with a multi-lead recording.

The iRhythm MCOT (Mobile Cardiac Outpatient Telemetry) service, which provides real-time transmission via cellular modem, uses a 3-lead configuration that partially addresses the wide complex differentiation problem. For patients in whom the distinction between VT and SVT with aberrancy is the primary clinical question, a 3-lead MCOT monitor is preferable to the 2-electrode single-lead Zio Patch.

10.2 The Artificial Intelligence Interpretation Layer

The iRhythm proprietary AI algorithm processes the full 14-day ECG recording and generates the Zio Report, which includes:

• A summary of detected arrhythmias by type, duration, and time of occurrence
• A table of the longest and most symptomatic episodes of each arrhythmia category
• The percentage of the monitoring period spent in each rhythm
• Patient-triggered events correlated with symptom logs
• A statement of “clinically significant findings” flagged for physician review

The AI algorithm has been validated against cardiologist-adjudicated review in multiple studies. Sensitivity for AF detection is greater than 95% for episodes lasting at least 30 seconds. The algorithm’s sensitivity for very short AF runs (less than 30 seconds) and for atrial high rate episodes (AHREs) characteristic of subclinical AF is lower and the clinical significance of these brief episodes remains uncertain 4 / Promising .

The AI pre-interpretation step in the Zio Report does not replace cardiologist review. iRhythm’s workflow includes a board-certified cardiac technician review of AI-flagged findings before the report is released to the ordering physician. However, the cardiologist interpreting the final report should understand that both human and machine review have occurred, and that the report represents a curated summary, not the raw 14-day ECG trace in full. Downloading and reviewing full ECG excerpts (available in the portal) is advisable for any finding that will change management.

10.3 Comparison with 48-Hour and 7-Day Holter Monitors

The clinical literature comparing Zio Patch yield to shorter monitoring windows is consistent: longer monitoring detects more arrhythmias, and the yield increment is largest in the first extension beyond 24 hours and again beyond 7 days. The specific data from the MCERIT framework study (Linzer M, et al., Ann Intern Med 1990; DOI: 10.7326/0003-4819-113-1-53) and subsequent Zio Patch yield analyses support the following hierarchy:

The table illustrates the trade-off: longer monitoring detects more arrhythmia, but at 14 days the Zio Patch captures the large majority of paroxysmal AF episodes that would be identified by shorter windows. For suspected paroxysmal AF, 14 days is the sweet spot between yield and feasibility. For very infrequent arrhythmias that occur less than once per two weeks, implantable loop recording is the appropriate next step.

Common Clinical Scenarios and the Zio Decision

11.1 Palpitations with Normal Holter: The Zio Upgrade

A 53-year-old man in Champaign reports episodic racing heart that lasts 20-30 minutes and occurs approximately once every 10-14 days. His resting 12-lead ECG is normal. A 24-hour Holter shows only rare PVCs. His cardiologist orders a 14-day Zio Patch. On day 9, the patient marks a symptom at 9:47 PM. The corresponding Zio recording shows a regular narrow complex tachycardia at 168 bpm lasting 23 minutes. The P-wave morphology in the single lead is consistent with AVNRT (pseudo-S wave pattern). The Zio Report flags this as supraventricular tachycardia and the patient is referred for electrophysiology evaluation.

This scenario describes a high-yield use case: episodic arrhythmia too infrequent for a 24-hour monitor to capture but frequent enough to be caught in 14 days. The Holter was appropriate first-line; the Zio Patch is the rational second step when the Holter is negative.

11.2 Post-Ablation Monitoring

After pulmonary vein isolation for AFib, the 2023 HRS/EHRA/ECAS ablation consensus recommends monitoring at 3 months, 6 months, and 12 months to assess for recurrence 5 / Solid . The Zio Patch is well-suited for this monitoring because:

• The 14-day window captures the most common early recurrence pattern (clustered AF episodes in the first 30-90 days post-ablation)
• The continuous recording catches asymptomatic recurrence, which constitutes up to 40% of post-ablation AF recurrence episodes
• The detailed report allows the cardiologist to assess AF burden (percentage of monitoring time in AF) rather than simply confirming presence or absence of AF

A patient who is in AF for 2 hours over 14 days has a very different clinical picture than one who is in AF for 8 hours per day. Both would be “AF recurrence” on a binary outcome measure; the Zio Patch quantifies the difference.

11.3 Syncope Evaluation

Syncope has a broad differential diagnosis, only a fraction of which is arrhythmic. In patients with an unexplained syncope, the initial evaluation includes history, physical examination, orthostatic blood pressure measurement, resting 12-lead ECG, and echocardiogram. When these are unrevealing, ambulatory monitoring is the next step, with the goal of correlating a syncopal episode with a rhythm finding.

The challenge: syncope severe enough to cause falls or loss of consciousness may occur infrequently. A 14-day Zio Patch may not capture the causative arrhythmia if syncopal episodes occur months apart. In the ISSUE-3 trial paradigm (ILR-guided management for syncope), the implantable loop recorder captured causative arrhythmias in up to 30% of patients at 24 months of monitoring. For patients with frequent syncope (more than once every two weeks), the Zio Patch is reasonable first-line. For patients with syncope once every few months, the Zio Patch is unlikely to capture the event and ILR implantation should be considered earlier in the workup.

Illinois Access and the Zio Mail-In Model

12.1 Why the Mail-In Model Matters in Rural Illinois

The traditional ambulatory ECG monitoring workflow requires the patient to visit a cardiology clinic, be fitted with a monitor by a trained technician, return the monitor after the recording period, and wait for results. For patients in rural Illinois counties more than 60 miles from a cardiology center, this process requires multiple days of travel and time away from work. The Zio Patch’s mail-in model disrupts this workflow entirely.

The ordering physician (primary care or cardiology) places the order. iRhythm ships the patch with application instructions. The patient applies the patch at home. At 14 days, the patient removes the patch and mails it to iRhythm using the prepaid envelope. Results are available on the iRhythm portal within 24-48 hours of patch receipt. The entire workflow requires one physician-patient touchpoint (the order) and one patient action (patch application and mailing). The geographic barrier to extended ambulatory monitoring essentially disappears.

For the Carle Foundation Hospital network, which serves communities in Champaign, Decatur, Danville, and rural counties in between, this model has significantly increased the proportion of patients who complete their prescribed monitoring. Before mail-in availability, approximately 20-30% of patients in rural catchment areas never picked up their prescribed monitor from the cardiology clinic.

12.2 Cost and Insurance Coverage

The Zio Patch is covered by Medicare under CPT code 93245 (mobile cardiac telemetry, up to 30 days) when ordered for appropriate indications. Commercial insurance coverage is variable; major carriers including BCBS Illinois, Aetna, and UnitedHealthcare cover Zio Patch monitoring with appropriate ICD-10 diagnosis coding. The key billing distinction: the Zio XT is billed as a long-term continuous ECG monitor; the Zio AT (with real-time transmission capability) may be billed at a higher rate as mobile cardiac telemetry.

For uninsured patients, the cost of a 14-day Zio Patch is approximately $200-400 out-of-pocket depending on the service agreement. This is more than a standard 24-hour Holter but less expensive than an emergency department visit that might have been prompted by an untreated arrhythmia. The cost-effectiveness argument for extended monitoring in symptomatic patients is supported by the reduced downstream testing when a diagnosis is established early.

Zio Use Protocol

In a structured cardiovascular assessment, Zio Patch monitoring is ordered for any patient presenting with:

• Palpitations that are episodic, last more than 5 minutes, and have not been captured on previous monitoring
• Unexplained presyncope or syncope with a negative standard workup
• Unexplained fatigue in a patient with risk factors for paroxysmal AF
• Post-ablation surveillance at 3 months, 6 months, and 12 months
• Cryptogenic stroke risk assessment (pending ILR implantation if Zio is negative)

The clinical team reviews the iRhythm report within 48 hours of receipt. Clinically significant findings (AF burden greater than 1% of monitoring time, NSVT, advanced AV block, pause greater than 3 seconds) are escalated to the attending cardiologist within 4 hours. Patients in rural catchment areas are contacted by telemedicine to review results and discuss next steps without requiring in-person travel.

The Signal Check is fifteen questions mapping the cardiovascular risk pattern across the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.